



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,533	09/16/2003	Adam M. Gilbert	AM100279/WYNC-0677	3576
23377	7590	10/26/2006	EXAMINER	
WOODCOCK WASHBURN LLP ONE LIBERTY PLACE, 46TH FLOOR 1650 MARKET STREET PHILADELPHIA, PA 19103			BALLS, ROBERT J	
			ART UNIT	PAPER NUMBER
			1625	

DATE MAILED: 10/26/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450


APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/663,533	9/16/2003	Adam M. Gilbert	AM100279/WYNL-0677
EXAMINER			
Balls, Robert James			
ART UNIT		PAPER	
1625		20061024	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Applicants' corrected appeal brief containing an Evidence Appendix and Related Proceedings Appendix has been received and entered. The Examiner's Answer was mailed to applicants on March 9, 2006, a copy of which is attached hereto. There are no changes or additions to the Examiner's Answer.



R. James Balls  
Art Unit 1625

<b>Notification of Non-Compliant Appeal Brief (37 CFR 41.37)</b>	<b>Application No.</b> 10/663,533	<b>Applicant(s)</b> GILBERT ET AL	
	<b>Examiner</b> James Balls	<b>Art Unit</b> 1625	

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

The Appeal Brief filed on 11 April 2005 is defective for failure to comply with one or more provisions of 37 CFR 41.37.

To avoid dismissal of the appeal, applicant must file an amended brief or other appropriate correction (see MPEP 1205.03) within **ONE MONTH or THIRTY DAYS** from the mailing date of this Notification, whichever is longer.  
**EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136.**

1. ☒ The brief does not contain the items required under 37 CFR 41.37(c), or the items are not under the proper heading or in the proper order.
2. ☐ The brief does not contain a statement of the status of all claims, (e.g., rejected, allowed, withdrawn, objected to, canceled), or does not identify the appealed claims (37 CFR 41.37(c)(1)(iii)).
3. ☐ At least one amendment has been filed subsequent to the final rejection, and the brief does not contain a statement of the status of each such amendment (37 CFR 41.37(c)(1)(iv)).
4. ☐ (a) The brief does not contain a concise explanation of the subject matter defined in each of the independent claims involved in the appeal, referring to the specification by page and line number and to the drawings, if any, by reference characters; and/or (b) the brief fails to: (1) identify, for each independent claim involved in the appeal and for each dependent claim argued separately, every means plus function and step plus function under 35 U.S.C. 112, sixth paragraph, and/or (2) set forth the structure, material, or acts described in the specification as corresponding to each claimed function with reference to the specification by page and line number, and to the drawings, if any, by reference characters (37 CFR 41.37(c)(1)(v)).
5. ☐ The brief does not contain a concise statement of each ground of rejection presented for review (37 CFR 41.37(c)(1)(vi)).
6. ☐ The brief does not present an argument under a separate heading for each ground of rejection on appeal (37 CFR 41.37(c)(1)(vii)).
7. ☐ The brief does not contain a correct copy of the appealed claims as an appendix thereto (37 CFR 41.37(c)(1)(viii)).
8. ☐ The brief does not contain copies of the evidence submitted under 37 CFR 1.130, 1.131, or 1.132 or of any other evidence entered by the examiner and **relied upon by appellant in the appeal**, along with a statement setting forth where in the record that evidence was entered by the examiner, as an appendix thereto (37 CFR 41.37(c)(1)(ix)).
9. ☐ The brief does not contain copies of the decisions rendered by a court or the Board in the proceeding identified in the Related Appeals and Interferences section of the brief as an appendix thereto (37 CFR 41.37(c)(1)(x)).
10. ☐ Other (including any explanation in support of the above items):  
 \_\_\_\_\_

The appeal brief is not in accordance with 37 CFR §41.37(c)(1). Specifically, it does not include the headings, "Evidence Appendix" and "Related Proceedings Appendix." (See (9) and (10) below).

Appellants are hereby required to submit the missing "Evidence Appendix" and "Related Proceedings Appendix," as set forth in 37 CFR §41.37(c)(1)(ix) and 37 CFR §41.37(c)(1)(x).

To expedite prosecution, the examiner has considered the deficient appeal brief filed on April 11, 2005 and provided a Revised Examiner's Answer.

RJB

2



**UNITED STATES DEPARTMENT OF COMMERCE**

**U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO/ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
--------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT	PAPER
----------	-------

20060223

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,533	09/16/2003	Adam M. Gilbert	AM100279/WYNC-0677	3576
23377	7590	03/09/2006	EXAMINER	
WOODCOCK WASHBURN LLP ONE LIBERTY PLACE, 46TH FLOOR 1650 MARKET STREET PHILADELPHIA, PA 19103			BALLS, ROBERT J	
			ART UNIT	PAPER NUMBER
			1625	

DATE MAILED: 03/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**MAILED**  
**MAR 09 2006**  
**GROUP 1600**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/663,533  
Filing Date: September 16, 2003  
Appellant(s): GILBERT ET AL.

\_\_\_\_\_  
Wendy Choi

For Appellant

**REVISED EXAMINER'S ANSWER**

This Revised Examiner's Answer is in response to Applicant's appeal brief filed on April 11, 2005 and replaces the Examiner's Answer filed on July 11, 2005, which is vacated in accordance with The Board of Patent Appeals and Interferences' Order Returning Undocketed Appeal to Examiner.

## Table of Contents

1. Real Party in Interest.....	3
2. Related Appeals and Interferences.....	3
3. Status of Claims.....	3
4. Status of Amendments.....	3
5. Summary of Claimed Subject Matter.....	3
6. Grounds of Rejection to be Reviewed on Appeal.....	4
7. Argument.....	4
A. Grounds of Rejection.....	4
(a) The Breadth of the Claims.....	5
(b) The Nature of the Invention and Predictability in the Art.....	6
(c) The State of the Prior Art.....	7
(d) The Level of One of Ordinary Skill.....	7
(e) The Amount of Direction Provided by the Inventor.....	8
(f) The Existence of Working Examples.....	8
(g) The Quantity of Experimentation Needed to Make or Use the Invention Based on the Content of the Disclosure.....	8
B. Response to Applicants' Arguments.....	9
(a) The Nexus Between 5HT <sub>1A</sub> Receptor Antagonists and the Treatment of Alzheimer's Disease, Appetite Control, Disorders of Thermoregulation and Sleep Dysfunction.....	9
(b) Treating Conditions that Encompass Seemingly Opposite Characteristics with the Same Compound.....	12
(c) The Sufficiency of Representative Examples Establishing Compounds of Formula I as 5HT <sub>1A</sub> Receptor Antagonists.....	13
8. Claims Appendix.....	15
9. Evidence Appendix.....	16
10. Related Proceedings Appendix.....	17



**(1) REAL PARTY IN INTEREST**

Appellants' brief identifies Wyeth as the real party in interest.

**(2) RELATED APPEALS AND INTERFERENCES**

Appellants' brief states there are no related appeals or interferences pending.

The Board, however, may in its discretion require an explicit statement as to the existence of any related appeals and interferences.

**(3) STATUS OF CLAIMS**

Claims 1 – 25 and 27 – 32 are cancelled. Claims 26 and 33 – 52 are rejected.

There are no claims allowed, withdrawn, or presently under objection. The rejection of claims 26, 33 – 52 stand or fall together. Appellants' brief does not include a statement that this grouping of claims does not stand or fall together and reasons in support thereof. 37 CFR 1.192(c)(7).

**(4) STATUS OF AMENDMENTS**

The December 20, 2004 Amendment After Final Rejection has been entered.

**(5) SUMMARY OF CLAIMED SUBJECT MATTER**

Claims 26 and 33 – 52 are directed to a method of treating a subject suffering from a condition selected from Alzheimer's disease, appetite control, disorders of thermoregulation, and sleep dysfunction, comprising the step of providing to said

Art Unit: 1625

subject an effective amount of a compound of formula I, wherein formula I is described in the specification on page 1, line 26 to page 3, line 10.

**(6) GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL**

Claims 26, 33-52 are rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the enablement requirement.

The Board or Patent Appeals and Interferences must determine whether claims are properly rejected for failing to meet the requirements of 35 U.S.C. §112 when the claims encompass a broad genus of chemical compounds directed toward treating a multitude of unrelated diseases by contradicting physiological processes absent any evidence demonstrating such compound exists.

**(7) ARGUMENT**

**A. Grounds of Rejection**

Claims 26, 33-52 contain subject matter that was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The standard for determining whether the specification meets the enablement requirement was cast in the Supreme Court decision of *Mineral Separation v. Hyde*, 242 U.S. 261, 270 (1916), where the Supreme Court looked to whether the experimentation needed to practice an invention was undue or unreasonable. *Id.* An invention must be described so that any person skilled in the art can make and use the invention without undue experimentation.

*In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988). Courts rely on the following factors set out in *In re Wands* to determine whether undue experimentation is required to practice a claimed invention, i.e. whether the claimed invention is enabled: (a) The breadth of the claims; (b) The nature of the invention and predictability in the art; (c) The state of the prior art; (d) The level of one of ordinary skill; (e) The amount of direction provided by the inventor; (f) The existence of working examples; and (g) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. *Id.* The analysis must include consideration of all factors. It is improper to rely on only one of the above factors while ignoring one or more of the others. The analysis must consider all the evidence related to each of these factors, and any conclusion of nonenablement must be based on the evidence as a whole. *Id.* at 740, *Id.* at 1407.

**(a) The Breadth of the Claims**

The claims are broad due to the high number of compounds and diseases they embody. Formula I encompasses many different compounds due to the breadth of its variables (i.e.  $R^1$  and  $R^2$ ). Applicants assert that these numerous compounds are effective in treating a variety of unrelated diseases: Alzheimer's disease, appetite control (including the conflicting hyperphagia and hypophagia), any disorder of thermoregulation (including the opposing hypothermia and hyperthermia), and any sleep dysfunction (including the conflicting insomnia and narcolepsy).

**(b) The Nature of the Invention and Predictability in the Art**

The invention is physiological in nature as it is directed toward pharmaceuticals and treating diseases with those pharmaceuticals, an art which is highly unpredictable. "[T]he scope of enablement varies inversely with the degree of unpredictability of the factors involved," and physiological activity is generally considered to be an unpredictable factor. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). In the highly unpredictable pharmaceutical art, the required disclosure is greater than for the disclosure of an invention involving predictable factors such as mechanical or electrical elements. *In re Vaeck*, 20 USPQ 2d 1438 (CAFC 1991). The high degree of unpredictability is well recognized in the 5HT<sub>1A</sub> receptor ligand art. For example, a slight change in the structure of a compound can drastically alter its affinity and selectivity. Wijngaarden, *Recl. Trav. Chim. Pays-Bas*. 112:126-130 (1993), pages 129-130, Fig. 6, Fig. 7, Fig. 8. *In vitro* binding data do not necessarily reflect the *in vivo* activity under the much more complex physiological conditions. *Id.* Since the above studies (and the studies described Lanfumey et al., *Curr. Drug Targets—CNS & Neurological Dis.* 3:1-10 (2004) and Kwon et al., *Neurodegenerative Dis.* 1:113-52 (2004)) are based on 5HT<sub>1A</sub> antagonists that are structurally different from the instant compounds, one of ordinary skill in the art has little basis to extend the data in these references to the instant. These studies demonstrate the complex nature of the 5HT<sub>1A</sub> art and the high degree of unpredictability it entails.

**(c) The State of the Prior Art**

The prior art fails to show a relationship between 5HT<sub>1A</sub> agonists and all of the claimed diseases. Although some 5HT<sub>1A</sub> agonists have anxiological and antidepressant activity, the nexus between Alzheimer's disease, appetite control, disorders of thermoregulation, sleep dysfunction, and 5HT<sub>1A</sub> receptor antagonism is not established. For example, while 5HT<sub>1A</sub> receptor agonist evokes hypothermia, inhibition of 5HT<sub>1A</sub> synthesis and 5HT<sub>1A</sub> lesions do not prevent hypothermia in rats (Barnes et al. *Neuropharmacology*, 38:1083-1092 (1999), page 1092). Some of the responses elicited by the 5HT<sub>1A</sub> receptor agonist 8-OH-PAT, such as hyperphagia (Fletcher et al., *Psychopharmacology*, 100(2):188-94 (1990), abstract), and altered sexual behavior (Matuszewich et al., *Brain Research*, 820(1-2):55-62 (1999), abstract), are not reversed by a 5HT<sub>1A</sub> receptor antagonists, thereby suggesting that these effects are not mediated by the 5HT<sub>1A</sub> receptor and that the agonism/antagonism relationship is not straightforward and predictable. The prior art shows that there is no umbrella drug known to be effective in treating all the diseases/conditions claimed and demonstrates a lack of relationship between the claimed compounds and the diseases for which they are intended to treat.

**(d) The Level of One of Ordinary Skill**

The art requires a high level of skill to perform. 5HT<sub>1A</sub> receptors have subclasses differing in their structures, regional distribution, pharmacology, modes of actions, and functions (Wijngaarden et al.; Barnes et al., pages 1085-6).

**(e) The Amount of Direction Provided by the Inventor**

The evidence fails to show that the claimed compounds are capable of treating the claimed diseases. The specification merely discloses how to synthesize the claimed chemical compounds and provides 5HT<sub>1A</sub> transporter binding assays, 5HT<sub>1A</sub> receptor binding assays, and assays for the assessment of antagonist activity (see specification pages 9-10). Results are shown for Examples 1-11 on page 11 of the specification.

**(f) The Existence of Working Examples**

No working example exists showing that a claimed compound is effective at treating all the claimed diseases.

**(g) The Quantity of Experimentation Needed to Make or Use the Invention Based on the Content of the Disclosure**

The quantity of experimentation necessary to make or use the disclosed invention is high based on the breadth of the claims, the unpredictability of the art, the limited guidance in the specification, and the high skill required to practice the claimed invention. A person of ordinary skill in the art would be subjected to undue experimentation in order to make and use the invention, and therefore, the invention is not enabled.

## **B. Response to Applicants' Arguments**

### **a. The Nexus Between 5HT<sub>1A</sub> Receptor Antagonists and the Treatment of Alzheimer's Disease, Appetite Control, Disorders of Thermoregulation and Sleep Dysfunction**

The nexus between the treatment of the claimed diseases and the antagonism of 5HT<sub>1A</sub> receptor has not been predictably established, especially in view of the findings of Barnes et al. Barnes et al. shows that 5HT<sub>1A</sub> receptor agonists may evoke hypothermia but conversely, 5HT<sub>1A</sub> agonists do not prevent hypothermia in rats (Barnes et al., page 1092). Some of the responses elicited by the 5HT<sub>1A</sub> receptor agonist 8-OH-PAT such as hyperphagia (Fletcher et al., abstract) and altered sexual behavior (Matuszewich et al., abstract) are not reversed by a 5HT<sub>1A</sub> receptor antagonists, thereby suggesting that these effects are not mediated by the 5HT<sub>1A</sub> receptor and simple agonism/antagonism at the 5HT<sub>1A</sub> receptor is not predictive of disease outcome *in vivo*.

Appellants have not addressed the above reference. Instead, they cite the following references: (1) Lanfumey et al. and Kwon et al. to support a claim for Alzheimer's disease (published in 2004, which is after the instant effective filing date); (2) Moreau et al., *Brain Res. Bull.* 26(6):901-4 (1992) to support a claim directed to appetite control; (3) Ootsuka et al., *J. Physiol.* 552(1):303-14 (2003) to support a claim directed toward disorders of thermoregulation; and (4) Sorensen et al., *Behav. Brain Res.* 121(1-2):181-7 (2001) to support a claim directed toward sleep dysfunction. These references do not teach how the 5HT<sub>1A</sub> receptor is involved in these diseases and fails to show that antagonism of 5HT<sub>1A</sub> would have a predictable, therapeutic outcome on the diseases and symptoms encompassed by the claims.

(1) Lanfumey et al. and Kwon et al. were published after the effective filing date and are not considered.

(2) Moreau et al. teach that 5HT<sub>1A</sub> activation may decrease palatable food consumption in rats. Although the reference may support a claim drawn to decreasing palatable food intake, it does not support the present claims drawn to all types of 'appetite control' including both hyperphagia (abnormally increased appetite for and consumption of food) and hypophagia (abnormally decreased appetite for and consumption of food).

(3) Ootsuka et al. teach that 5HT<sub>1A</sub> activation may abolish body temperature decrease. Although this reference may support a claim drawn to hypothermia, it does not support the present claims drawn to any 'disorders of thermoregulation,' which includes the opposing hypothermia and hyperthermia.

(4) Sorensen et al. teach that 5HT<sub>1A</sub> activation may induce a decrease in REM sleep. Although this reference may support a claim drawn to narcolepsy, it does not support the present claims drawn to all types of 'sleep dysfunction,' which covers both insomnia and narcolepsy.

Since the claims recite broad general classes of diseases embracing opposing and conflicting conditions arising from diverse origins, one of ordinary skill in the art would not reasonably expect to use a single 5HT<sub>1A</sub> receptor antagonist compound to treat all the contradictory disorders encompassed by the instant claims.



With the filing of this Brief, Appellants have submitted **seven new references**, which should have been submitted in the earlier stages of the prosecution. Nonetheless, these references fail to provide the required support for the following reasons.

Reference 1: Applicants cite Schechter et al., *Curr. Pharm. Design*, 8:139-145 (2002) to support claims directed toward Alzheimer's Disease. However, this reference was published after the effective filing date and is therefore not reflective of the state of the art. Further, Schechter et al. only describes the **potential** use of 5HT<sub>1A</sub> receptor antagonists to treat cognitive dysfunction associated with Alzheimer's disease.

References 2 & 3: Applicants cite Ebenezer et al., *Physiol. Behav.* 67(2):213-7 (1999) to support claims directed toward appetite control. Ebenezer et al. teaches that the 5HT<sub>1A</sub> agonist 8-OH-DPAT causes a hyperphagic effect on satiated pigs and a hypophagic effect on fasted pigs. Furthermore, 5HT<sub>1A</sub> antagonist WAY 100635 reverses the effects. WAY 100635 by itself, however, has no significant effects on feeding, which is different from the findings of Moreau et al., who show that the 5HT<sub>1A</sub> antagonist (S)-UH-301 decreases palatable food consumption. These references highlight the unpredictability of the art and caution the extrapolation of results from one antagonist to another.

References 4 & 5: Applicants cite Brubacher et al., *Vet. Hum Toxicol.* 38(5):358-61 (1996) to support claims directed to disorders of thermoregulation. Brubacher et al. teach that excessive stimulation of 5HT<sub>1A</sub> leads to the excess serotonin associated with hyperthermia. Applicants have not shown that 5HT<sub>1A</sub> antagonists would abolish this effect. Brubacher et al.'s disclosure contradicts Oerther et al., *Neuroreport.*,

11(18):3949-51 (2000), who teach that hypothermia is caused by the 5HT<sub>1A</sub> agonist 8-OH-DPAT.

References 6 & 7: Applicants cite Bjorvatn et al., *Rev. Neurosci.* 9(4):265-73 (1998) and Gillin et al., *Psychopharmacology* (Berl.) 116(4):433-6 (1994) to support claims directed to sleep dysfunction. While Bjorvatn et al. demonstrates that systemic administration of 5HT<sub>1A</sub> agonist increases wakefulness and reduces slow wave sleep and REM sleep, and Gillin et al. show that a relatively selective 5HT<sub>1A</sub> agonist, ipsapirone, inhibits REM sleep, the references do not show the opposite effect, i.e. that these compounds are capable of inducing sleep. In view of these references, one of ordinary skill in the art would not use a 5HT<sub>1A</sub> antagonist to both increase and decrease sleep. Bjorvatn et al. even states that although 5HT<sub>1A</sub> has been implicated in the regulation of vigilance, whether 5HT<sub>1A</sub> is important for sleep or waking processes remains controversial (Bjorvatn et al., abstract, first sentence).

Since the claims recite broad general classes of diseases embracing opposing and conflicting conditions arising from diverse origins, one of ordinary skill in the art would not reasonably expect to use a single 5HT<sub>1A</sub> receptor antagonist compound to treat all the contradictory disorders encompassed by the instant claims.

**b. Treating Conditions that Encompass Seemingly Opposite Characteristics With the Same Compound**

Appellants submit that it is not illogical to treat opposing conditions with the same compound and that it is widely recognized that a compound may serve to restore or ensure homeostasis with respect to a given physiological system. Undoubtedly, negative feedback is an important part of homeostasis. In some cases, a single

compound can act as both an agonist and an antagonist and is useful in treating conflicting conditions. In the instant case, however, there is no evidence showing that the claimed compounds are capable of treating opposing diseases. Conversely, the prior art demonstrates the opposite is true; that these compounds generally do not evoke opposing results. Furthermore, the specification fails to disclose any guidance or direction demonstrating how to use the claimed compounds to treat opposing diseases. Those of ordinary skill in the art recognize that single compounds capable of treating opposing symptoms are highly condition specific—a slight change in conditions can have dramatic effect on the body's physiological response to that compound. The different critical conditions required to achieve opposite responses have not been described in the specification nor disclosed in the prior art. Therefore, in the absence of more guidance setting forth the condition required to treat opposing symptoms, one of ordinary skill in the art would be subjected to undue experimentation in order to practice the invention as claimed.

**c. The Sufficiency of Representative Examples Establishing Compounds of Formula I as 5HT<sub>1A</sub> Receptor Antagonists**

Appellants submit that the two disclosed assays (3H-paroxetine binding assay and [<sup>35</sup>S]-GTPγS binding assay) show that the compounds of formula I are capable of treating all of the conflicting diseases encompassed by the claims. However, these assays merely demonstrate that compounds of formula I are involved in 5HT<sub>1A</sub> binding, nothing more. As demonstrated previously, there is a high degree of unpredictability in the 5HT<sub>1A</sub> receptor antagonist art and compounds of similar structure often exhibit very different biological activities. *In vitro* antagonism does not accurately predict *in vivo*

Art Unit: 1625

efficacy. Wijngaarden et al., pages 129-130, Fig. 6, Fig. 7, Fig. 8. One of ordinary skill in the art therefore would have little basis to extrapolate results from the tested compounds to other antagonist compounds of dissimilar structure.

The nexus between 5HT<sub>1A</sub> receptor antagonists and treatment of Alzheimer's disease, appetite control, disorders of thermoregulation and sleep dysfunction has not been predictably established. The breadth of the claims is not commensurate in scope with that of the objective enablement and the specification does not provide sufficient guidance and teaching to enable one of ordinary skill in the art to use the invention as claimed without undue experimentation.

For these reasons the rejections should be sustained.

Application/Control Number: 10/663,533  
Art Unit: 1625

Page 15

**(8) CLAIM APPENDIX**

A copy of the appealed claims is attached hereto.

**(9) EVIDENCE APPENDIX**

Barnes et al. <i>Neuropharmacology</i> , 38:1083-1092 (1999).....	7, 9
Brubacher et al., <i>Vet. Hum Toxicol.</i> 38(5):358-61 (1996).....	11
Bjorvatn et al., <i>Rev. Neurosci.</i> 9(4):265-73 (1998).....	12
Ebenezer et al., <i>Physiol. Behav.</i> 67(2):213-7 (1999).....	11
Fletcher et al., <i>Psychopharmacology</i> , 100(2):188-94 (1990).....	7, 9
Gillin et al., <i>Psychopharmacology (Berl.)</i> 116(4):433-6 (1994).....	12
Kwon et al., <i>Neurodegenerative Dis.</i> 1:113-52 (2004) .....	6, 9
Lanfumeey et al., <i>Curr. Drug Targets—CNS &amp; Neur. Dis.</i> 3:1-10 (2004).....	6, 9, 10
Matuszewich et al., <i>Brain Research</i> , 820(1-2):55-62 (1999).....	7, 9
Moreau et al., <i>Brain Res. Bull.</i> 26(6):901-4 (1992).....	9, 10, 11
Oerther et al., <i>Neuroreport.</i> , 11(18):3949-51 (2000).....	11
Ootsuka et al., <i>J. Physiol.</i> 552(1):303-14 (2003) .....	9, 10
Schechter et al., <i>Curr. Pharm. Design</i> , 8:139-145 (2002).....	11
Sorensen et al., <i>Behav. Brain Res.</i> 121(1-2):181-7 (2001).....	9, 10
Wijngaarden et al., <i>Recl. Trav. Chim. Pays-Bas.</i> 112:126-130 (1993).....	6, 7, 14


**(10) REATED PROCEEDINGS INDEX**


There are no related proceedings.

James Balls  
Examiner  
Art Unit 1625

WOODCOCK WASHBURN LLP  
ONE LIBERTY PLACE, 46TH FLOOR  
1650 MARKET STREET  
PHILADELPHIA, PA 19103

Respectfully submitted,

  
Cecelia Tsang  
Supervisory Patent Examiner  
Art Unit 1625  
February 23, 2006

  
CEIL CHANG  
PRIMARY EXAMINER  
GROUP 1200-1625